Authors
Jean Yves Reginster
Cyrus Cooper
Marc Hochberg
Jean Pierre Pelletier
R Rizzoli
John A. Kanis, Australian Catholic UniversityFollow
Eric Abadie
E. Maheu
Maria Luisa Brandi
J. P. Devogelaer
J. Branco
G. Herrero-Beaumont
Pieter D'Hooghe
O. Bruyère
Publication Date
2015
Publication Details
Reginster, J. Y, Cooper, C., Hochberg, M., Pelletier, J. P, Rizzoli, R., Kanis, J. A, Abadie, E., Maheu, E., Brandi, M. L, Devogelaer, J. P, Branco, J., Herrero-Beaumont, G., D'Hooghe, P. & Bruyère, O. (2015). Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis. Current Medical Research and Opinion,31(5), 1041-1045. United Kingdom: Informa Healthcare. Retrieved from https://doi.org/10.1185/03007995.2015.1027183
Abstract
Despite the near concurrent publication by influential scientific organizations, there are important differences in interpretation of the evidence base and the conclusions derived from the recent Osteoarthritis Research Society International (OARSI) guidelines for the management of knee osteoarthritis, the American College of Rheumatology (ACR) guidelines (concerning also hip and hand osteoarthritis) and the algorithm recommendations by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). This is particularly evident for the drug class of symptomatic slow-acting drugs in osteoarthritis. In this paper, we highlight these differences and try to understand where they derive from, proposing an evidence-based interpretation.
School/Institute
Institute for Health and Ageing
Document Type
Journal Article
Access Rights
ERA Access